Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap |
|---|
| Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
LG LGND LIGAND PHARMACEUTICALS INC FY ended Feb 24, 2026 | $286.92 | $5.72B | $5.31B | $268.09M | $207.82M | $124.45M | 46.81x | 21.34x | 25.49x |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $42.86 | $2.50B | $2.11B | $868.45M | $262.93M | $158.69M | 15.82x | 2.87x | 7.58x |
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $44.03 | $2.56B | $2.08B | $718.95M | $60.82M | -$38.55M | -64.75x | 3.56x | 29.46x |
VT VTRS Viatris Inc FY ended Feb 23, 2026 | $17.09 | $19.63B | $31.03B | $14.30B | -$469.30M | -$3.51B | -5.70x | 1.37x | 1331.84x |
OG OGN Organon & Co. FY ended Feb 17, 2026 | $13.77 | $3.62B | $13.79B | $6.22B | $1.29B | $187.00M | 19.13x | 0.58x | 10.69x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $128.83 | $25.74B | $23.84B | $5.14B | $1.76B | $1.29B | 20.10x | 5.01x | 13.54x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 238.81x | 6/6 | -$7.71B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 5.79x | 6/6 | $1.24B | $2.94 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 5.23x | 6/6 | -$203.03M | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
LG LGND LIGAND PHARMACEUTICALS INC FY ended Feb 24, 2026 | $286.92 | $5.72B | $5.31B | $268.09M | $207.82M | $124.45M | 46.81x | 21.34x | 25.49x |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $42.86 | $2.50B | $2.11B | $868.45M | $262.93M | $158.69M | 15.82x | 2.87x | 7.58x |
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $44.03 | $2.56B | $2.08B | $718.95M | $60.82M | -$38.55M | -64.75x | 3.56x | 29.46x |
VT VTRS Viatris Inc FY ended Feb 23, 2026 | $17.09 | $19.63B | $31.03B | $14.30B | -$469.30M | -$3.51B | -5.70x | 1.37x | 1331.84x |
OG OGN Organon & Co. FY ended Feb 17, 2026 | $13.77 | $3.62B | $13.79B | $6.22B | $1.29B | $187.00M | 19.13x | 0.58x | 10.69x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $128.83 | $25.74B | $23.84B | $5.14B | $1.76B | $1.29B | 20.10x | 5.01x | 13.54x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 238.81x | 6/6 | -$7.71B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 5.79x | 6/6 | $1.24B | $2.94 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 5.23x | 6/6 | -$203.03M | — | Target fundamentals do not produce a usable positive equity value. |
